Search filters

Filters

Clear All

Phase

  • 24
  • 4
  • 23
  • 1
  • 32
  • 1
  • 10
  • 98
  • 62
  • 1
  • 1
  • 96

Found 98 Vision Loss trials

A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)

18 years - 75 years
All genders
Phase 2
Interventional
The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.
 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS-IgAN)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS-IgAN)

18 years - 80 years
All genders
Phase 3
This study will use a new investigational study drug called OMS721 in people with Immunoglobulin A (IgA) Nephropathy. This kidney disease produces abnormal amounts of a protein called IgA in the kidney that damage the filtering units or glomeruli. Glomeruli are tiny filtering units in the kidney that remove excess …
 A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)

1 years - 100 years
All genders
Phase 3
The research study is being conducted to see how well the investigational drug, Nefecon, works for the treatment of your kidney disease and more specific for patients with "primary immunoglobulin A nephropathy," called IgAN.

A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an open-label extension

18 years - 80 years
All genders
Phase 2
SAR443820 is a selective, orally bioavailable, central nervous system (CNS)-penetrant, receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor. The aim of this Phase 2 study is to determine the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SAR443820 in treating adult participants with amyotrophic lateral sclerosis (ALS).
 PROTECT- study of the efficacy and safety of sparsentan for the treatment of Immunoglobulin A (IgAN) nephropathy

PROTECT- study of the efficacy and safety of sparsentan for the treatment of Immunoglobulin A (IgAN) nephropathy

18 years - 99 years
All genders
Phase 3
Immunoglobulin A nephropathy (IgAN) is a rare disease that affects the kidneys, mostly in teens and adults. Kidneys are important to your health because they filter waste materials such as salts, toxins and water out of the blood. The waste is passed out of your body as urine (pee). IgAN …

A phase 3 multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual -cell function

All genders
The objective of this clinical trial is to assess whether ladarixin treatment is effective in preserving -cell function and delaying the progression of T1D in adolescent and adult patients. The safety of ladarixin in the specific clinical setting will be also evaluated.

A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy and an Open-labeled Long-term Safety Extension Treatment

18 years - 74 years
All genders
Phase 3
Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy and an Open-labeled Long-term Safety Extension Treatment with Seltorexant

Evaluating the Efficacy and Safety of Long-Acting Lenacapavir for HIV PrEP

16 years - 100 years
Male
Phase 3
The primary objective of the PURPOSE2 study is to evaluate the efficacy of lenacapavir (LEN) in preventing the risk of contracting human immunodeficiency virus (HIV). The study will be conducted in 2 parts: a cross-sectional study (Incidence Phase) and a double-blind, randomized study (Randomized Phase).1) The Incidence Phase will include …

Meningococcal Group B vaccine Bexsero for Gonorrhea Prevention

18 years - 50 years
All genders
Phase 2
The main purpose of this study is to learn if a vaccine that is given as two shots (injections) to prevent spinal meningitis (an infection of the lining of the brain and spinal cord caused by Neisseria meningitidis type B) might also work in preventing gonorrhea (caused by Neisseria gonorrhoeae). …
 A Multiple-Site  Phase 1/2  Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients with Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene

A Multiple-Site Phase 1/2 Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients with Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene

All genders
Phase 2
Achromatopsia is an inherited retinal disorder characterized by markedly reduced visual acuity, nystagmus, photoaversion (intolerance to bright light), a small central scotoma, eccentric viewing, and complete or severe loss of color discrimination. The genetic mutations of the disease can be established in the majority of individuals. Approximately 50% are caused …
1 - 10 of 98